Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zomedica Corp (NASDAQ: ZOM) shares are trading higher by 14% at $0.40 during Monday's session after the company reported fourth-quarter sales of $4.10 million. Zomedica says PulseVet revenue grew to $4.0 million in the fourth-quarter 2021, an increase of 66% over its fourth-quarter.

Why Zomedica Shares Are Rising

Ann Arbor, Michigan--(Newsfile Corp. - February 28, 2022) - Zomedica (AMEX: ZOM) today announced that Larry Heaton, CEO will be attending the Q1 Virtual Investor Summit. During the presentation, Zomedica's Chief Executive Officer, Larry Heaton, will highlight the Company's recent integration of PulseVet, Inc., it's progress with the TRUFORMA product line, and the resulting transformational business strategy and partnerships, and the broader going-forward corporate vision. The presentation will be webcast and archived in the...

Zomedica Announces Participation in the Q1 Virtual Investor Summit

ANN ARBOR, MI / ACCESSWIRE / February 25, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced revenues and gross margin for the Fourth Quarter and Full Year 2021. Total revenue for the Fourth Quarter and Full Year 2021 was $4.1 million, compared to $0 in both periods in 2020.

Zomedica Announces Fourth Quarter and 2021 Revenues of $4.1 Million; 73.9% Gross Margin

Didi Global

Tellurian

Penny stocks, are they worth buying or not this year? The post Are Penny Stocks Worth Buying in 2022?

Are Penny Stocks Worth Buying in 2022?

The veterinary diagnostics company didn't see its shares jump until a spike on Thursday.

Why Zomedica Stock Soared 72.4% This Week

Camber Energy

Exela Technologies

What penny stocks are investors watching as Russia-Ukraine tensions rise? The post Top Penny Stocks to Watch as Ukraine-Russia Conflict Intensifies  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch as Ukraine-Russia Conflict Intensifies

Harmony Gold Mining Co Ltd

RLX Technology

Check these three Reddit penny stocks to watch right now The post Reddit Penny Stocks That Should Be On Your Watchlist  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Reddit Penny Stocks That Should Be On Your Watchlist

ZOM stock has been a toxic asset for nearly a year, and Zomedica isn't giving investors much to get enthused about. The post Zomedica's Shareholders Should Be Worried About the Outlook of ZOM Stock appeared first on InvestorPlace.

Zomedica's Shareholders Should Be Worried About the Outlook of ZOM Stock

ANN ARBOR, MI / ACCESSWIRE / February 15, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Adrian Lock, Vice President and General Manager, will lead the Company's sales organization, including Zomedica field sales personnel, sales management and professional service veterinarians, as well as existing PulseVet sales personnel. As the founding Chief Executive Officer of PulseVet, Mr.

Zomedica Appoints Adrian Lock to Lead Sales Organization

Denison Mines

TDH Hlds

Can these penny stocks push up this week? The post Best Penny Stocks to Buy in Mid-February?

Best Penny Stocks to Buy in Mid-February? 3 to Watch

ANN ARBOR, MI / ACCESSWIRE / February 9, 2022 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced new additions to its management team. Management Team Development The Company has recently welcomed new additions to the management team to expand its capabilities to prepare for future growth both organically and through business development activities.

Zomedica Announces Management Team Additions

Phunware Inc

Check these penny stocks out for your watchlist next week The post High-Performing Penny Stocks That You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

High-Performing Penny Stocks That You Need to Know About

Southwestern Energy

Exicure Inc

Check these Reddit penny stocks out for your watchlist right now The post Popular Reddit Penny Stocks to Watch In February 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Reddit Penny Stocks to Watch In February 2022

ANN ARBOR, MI / ACCESSWIRE / January 27, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today provided an update on its marketing activities during the first quarter of 2022. PulseVet Sales & Marketing Integration Sales and marketing management from both Zomedica and PulseVet completed PulseVet sales training for Zomedica's 18-strong field sales organization on the eve of the 2022 VMX Veterinary Meeting and Expo in Orlando, Florida January 16-19, 2022.

Zomedica Provides Updates on PulseVet Sales & Marketing Integration and Marketing Activities for the First Quarter of 2022

Although ZOM stock has some exciting news to undergird its price tag, that hardly anything has changed is worrying. The post Zomedica Stock Should Have Popped on This Latest Acquisition, so Beware appeared first on InvestorPlace.

Zomedica Stock Should Have Popped on This Latest Acquisition, so Beware

Jaguar Health

China Rapid Finance

Check these three under $1 penny stocks out for your watchlist The post 3 Penny Stocks to Watch Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch Under $1 Right Now

ANN ARBOR, MI / ACCESSWIRE / January 10, 2022 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, today issued the following letter from Larry Heaton, Chief Executive Officer, updating Zomedica's shareholders regarding several key activities and events: Dear Zomedica Shareholders, With just over 60 days in the role of Chief Executive Officer of Zomedica, I'm writing to share my perspective on the Company, its progress and opportunities. While we are currently conducting a robust review of our strategic plans, I thought you might appreciate some current insights now.

Zomedica CEO Provides Update to Shareholders

ZOM stock is far from a market darling, but an underreported acquisition could breathe new life into Zomedia's struggling business. The post There's a Reason to Consider Buying Zomedica, and It's a Real Shocker appeared first on InvestorPlace.

There's a Reason to Consider Buying Zomedica, and It's a Real Shocker

The veterinary diagnostics company has been a volatile stock.

Why Shares of Zomedica Corp. Dropped 22.5% in December

The dismal run of ZOM Stock likely to continue for the foreseeable future, until it meaningfully improves its top and bottom-line numbers. The post Zomedica Remains a Speculative Play in the Veterinary Field appeared first on InvestorPlace.

Zomedica Remains a Speculative Play in the Veterinary Field

Vinco Ventures

Transocean

Can penny stocks continue to make gains in 2022? The post 3 Hot Penny Stocks to Watch in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Watch in 2022

AMC Entertainment

BlackBerry

Bed Bath & Beyond

Clover Health Investments

GameStop

SNDL Inc.

Tesla

Wish

XpresSpa Group

Retail investors continue to drive the price of meme stocks higher. So it's time to look at 10 meme stocks and consider how they'll fare in 2022 The post Top 10 Meme Stocks of 2021 and How They'll Fare in 2022 appeared first on InvestorPlace.

Top 10 Meme Stocks of 2021 and How They'll Fare in 2022

ANN ARBOR, MI / ACCESSWIRE / December 15, 2021 / Zomedica Corp. (NYSE American:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced today that Larry Heaton, Chief Executive Officer, will present a company overview at the upcoming virtual H.C. Wainwright BioConnect 2022 Conference, scheduled for January 10-13, 2022.

Zomedica to Present at H.C. Wainwright BioConnect 2022 Conference

Carnival

DraftKings

MicroVision

Peloton

Someday, the challenges and hurdles affecting them could clear up. But for now, consider this group of seven popular plays stocks to avoid.

7 Tempting Stocks to Avoid Until These Key Issues Get Ironed Out

Early in 2021, ZOM stock was part of the meme stock trade. But recent catalysts suggest it may be time to view it as an investment.

News for Zomedica Stock (ZOM)